Blt 3

Dosage for tetracaine is highly individualized and must be determined by a qualified medical professional. The amount used depends on the area to be anesthetized, the vascularity of the tissues, and the specific procedure.

• For Ophthalmic Procedures: For short-term procedures like tonometry, 1 or 2 drops of the 0.5% solution are typically instilled into the eye just before the procedure. For minor surgical procedures like foreign body removal, 1 or 2 drops may be applied every 5 to 10 minutes for 3 doses.
• For Spinal Anesthesia: The dose varies based on the desired level of anesthesia. For lower extremity surgery, a dose of 5 mg to 10 mg is common. For procedures involving the lower abdomen, 12 mg to 15 mg may be used. These doses are typically administered as a 1% solution diluted with dextrose to control the spread of the drug in the spinal canal.
• For Topical Mucous Membrane Use: The lowest concentration and volume necessary to produce the desired effect should be used. Maximum adult doses for topical application should generally not exceed 20 mg to 50 mg to avoid systemic toxicity.

Tetracaine must be used with extreme caution in pediatric patients.

• Ophthalmic Use: Dosage is generally similar to adults (1-2 drops), but the child must be monitored closely for systemic absorption.
• Topical Skin Use: In children, the surface area covered and the duration of application must be strictly limited. Healthcare providers often use weight-based calculations to ensure the total dose does not exceed safe limits (e.g., 1 mg/kg).
• Spinal Anesthesia: While tetracaine can be used in pediatric spinal anesthesia, it is less common than in adults and requires specialized pediatric dosing protocols managed by a pediatric anesthesiologist.

Renal Impairment

While tetracaine is metabolized in the plasma, its metabolites are cleared by the kidneys. No specific dose adjustments are typically required for a single dose in patients with renal impairment, but caution is advised with repeated administrations to avoid metabolite accumulation.

Hepatic Impairment

Because tetracaine is metabolized by plasma pseudocholinesterase rather than liver enzymes, patients with liver disease are generally at no higher risk for toxicity than healthy patients, provided their plasma esterase levels are normal. However, severe liver disease can sometimes lead to decreased production of these plasma enzymes, which would necessitate a dose reduction.

Elderly Patients

Elderly patients may be more sensitive to the effects of spinal anesthesia, including the risk of low blood pressure (hypotension). Healthcare providers often reduce the dose for spinal anesthesia in patients over the age of 65 to ensure safety.

Tetracaine is almost always administered by a healthcare professional in a clinical setting.

• Ophthalmic Drops: If you are using these at home (rarely prescribed for home use), do not touch the dropper tip to any surface, including the eye. Wash your hands before and after use.
• Topical Creams: Apply only to the area directed by your doctor. Do not cover the area with a bandage or heat wrap unless specifically told to do so, as this can increase absorption into the bloodstream and lead to dangerous side effects.
• Storage: Store tetracaine products at room temperature, away from light and moisture. Some formulations may require refrigeration; always check the specific product label.

Since tetracaine is usually administered for a specific procedure by a doctor, missing a dose is unlikely. If you are on a schedule for topical application and miss a dose, apply it as soon as you remember. If it is almost time for the next dose, skip the missed one. Do not apply double the amount to make up for a missed dose.

An overdose of tetracaine can lead to Local Anesthetic Systemic Toxicity (LAST). This is a medical emergency.

• Signs of Overdose: Numbness of the tongue, metallic taste, ringing in the ears (tinnitus), dizziness, blurred vision, tremors, or seizures. In severe cases, it can lead to respiratory arrest and cardiac collapse.
• Emergency Measures: If an overdose is suspected, the administration must be stopped immediately. Emergency support including oxygen, airway management, and medications to control seizures or support the heart (such as lipid emulsion therapy) will be initiated by medical staff.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or apply topical tetracaine to large areas of the body without medical guidance.

When tetracaine is used as an eye drop or topical agent, certain localized reactions are very common. These are usually temporary and resolve shortly after the procedure.

• Stinging and Burning: Upon application to the eye or mucous membranes, a sharp stinging or burning sensation is reported by a majority of patients. This typically lasts for 30 to 60 seconds.
• Redness (Hyperemia): The blood vessels in the eye or on the skin may dilate, leading to a temporary red appearance.
• Lacrimation: Increased tearing is a common reflex response to the initial irritation of the eye drops.

• Contact Dermatitis: Some patients may develop a localized rash, itching, or swelling at the site of topical application.
• Photophobia: After ophthalmic use, your eyes may become temporarily sensitive to bright light.
• Blurred Vision: The anesthetic effect can temporarily interfere with the eye's ability to focus or may cause slight swelling of the cornea.
• Nausea: Especially common following spinal anesthesia as the body adjusts to the numbing effect and changes in blood pressure.

• Corneal Opacification: With repeated use of tetracaine eye drops, the surface of the eye (cornea) can become cloudy, leading to permanent vision loss.
• Methemoglobinemia: A rare blood disorder where the blood cannot effectively carry oxygen. Symptoms include bluish skin (cyanosis), headache, and fatigue.
• Severe Allergic Reactions: While rare, some individuals may develop hives, difficulty breathing, or swelling of the face and throat.

> Warning: Stop using Tetracaine and call your doctor immediately or seek emergency care if you experience any of the following:

• Central Nervous System Toxicity: Symptoms such as tremors, involuntary muscle twitching, or seizures. This indicates that the drug has reached high levels in the brain.
• Cardiovascular Collapse: A sudden drop in blood pressure, slow heart rate (bradycardia), or irregular heart rhythms. This is a sign of systemic toxicity affecting the heart muscle.
• Anaphylaxis: A life-threatening allergic reaction characterized by a rapid pulse, swelling of the airway, and a sharp drop in blood pressure.
• Severe Eye Pain: If eye pain increases or vision does not return to normal after the anesthetic should have worn off, this could indicate corneal damage.
• Respiratory Distress: Difficulty breathing or a feeling of 'air hunger' can occur if the anesthetic spreads too high in the spinal column or if a systemic reaction occurs.

Tetracaine is intended for acute, short-term use. It is never intended for chronic use.

• Ocular Keratopathy: Prolonged use of tetracaine eye drops can cause the cornea to soften and break down (keratopathy). This can lead to corneal ulcers, scarring, and permanent blindness. This is why tetracaine drops are never prescribed for home use to manage chronic eye pain.
• Sensitization: Repeated exposure to tetracaine can cause a person to become allergic to it and other related 'ester' anesthetics.

At this time, tetracaine does not carry a specific FDA Black Box Warning. However, it does carry significant 'Warnings and Precautions' regarding its potential for systemic toxicity and the absolute prohibition of prolonged ophthalmic use. Healthcare providers are trained to monitor for Local Anesthetic Systemic Toxicity (LAST) whenever tetracaine is administered in significant doses.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Adverse events can also be reported to the FDA at 1-800-FDA-1088.

Tetracaine is a potent medication that must be handled with care. The most critical safety point for patients to understand is that tetracaine is for professional use only. Because it numbs the area, it eliminates the body's natural 'warning signals' (like pain), which can lead to accidental injury. For example, if your eye is numbed, you might scratch the cornea without realizing it because you cannot feel the irritation.

No FDA black box warnings for Tetracaine. However, the lack of a black box warning does not imply that the drug is without risk. The potential for systemic toxicity and severe ocular damage is well-documented in clinical literature.

• Allergic Reactions / Anaphylaxis Risk: Tetracaine is an ester-type anesthetic. Patients who are allergic to other ester anesthetics (like procaine or benzocaine) or to para-aminobenzoic acid (PABA) are at a high risk of cross-sensitivity. Always inform your doctor if you have had a reaction to any numbing medication in the past.
• Corneal Toxicity: In ophthalmic use, repeated application can lead to permanent corneal damage. It is strictly prohibited to use tetracaine for self-medication of eye pain.
• Systemic Toxicity (LAST): If tetracaine is absorbed into the bloodstream too quickly, it can affect the central nervous system and the heart. This is more common when the drug is applied to broken skin or large surface areas.
• Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use. This condition reduces the oxygen-carrying capacity of the blood and can be fatal if not treated promptly. Risk is higher in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• Central Nervous System Disorders: Patients with a history of seizures or other CNS disorders should be monitored closely, as tetracaine can lower the seizure threshold if systemic absorption occurs.

When tetracaine is used for spinal anesthesia or in large topical doses, healthcare providers will monitor the following:

• Vital Signs: Continuous monitoring of blood pressure, heart rate, and oxygen saturation (SpO2).
• Electrocardiogram (ECG): To detect any heart rhythm disturbances.
• Neurological Status: Monitoring for signs of CNS toxicity like agitation or twitching.
• Ophthalmic Exams: If used in the eye, the doctor will check the cornea for any signs of irritation or damage before you leave the clinic.

You should not drive or operate heavy machinery until the effects of tetracaine have completely worn off. If used in the eye, your vision may be blurred and your depth perception may be altered. If used for spinal anesthesia, your motor skills and coordination will be significantly impaired for several hours.

While there is no direct chemical interaction between tetracaine and alcohol, alcohol can increase the risk of low blood pressure and dizziness, especially following spinal anesthesia. It is generally advised to avoid alcohol for at least 24 hours after receiving tetracaine anesthesia.

Tetracaine is used as a single-dose or short-term treatment. There is no risk of a 'withdrawal syndrome' or a need for tapering. However, as the medication wears off, you may experience a return of pain or a 'pins and needles' sensation (paresthesia). Your doctor will provide instructions for managing post-procedure pain.

> Important: Discuss all your medical conditions, including any history of heart disease or allergies, with your healthcare provider before starting Tetracaine.

• Sulfonamides (Sulfa Drugs): Tetracaine is metabolized into para-aminobenzoic acid (PABA). PABA can directly inhibit the action of sulfonamide antibiotics (such as sulfamethoxazole). If you are taking sulfa drugs for an infection, tetracaine may cause the antibiotic to fail. These should not be used together if the antibiotic effect is critical.
• Cholinesterase Inhibitors: Medications used to treat myasthenia gravis or Alzheimer's (like neostigmine or pyridostigmine) can inhibit the enzyme (pseudocholinesterase) that breaks down tetracaine. This can lead to dangerously high levels of tetracaine in the blood and increased risk of toxicity.

• Other Local Anesthetics: Using tetracaine alongside other local anesthetics (like lidocaine or bupivacaine) can have an additive effect. This increases the total 'anesthetic load' on the body and significantly raises the risk of Local Anesthetic Systemic Toxicity (LAST).
• Antiarrhythmic Drugs: Since tetracaine acts on sodium channels in the heart, using it with other antiarrhythmics (like amiodarone or mexiletine) can lead to additive effects on heart conduction, potentially causing heart block or dangerous arrhythmias.

• Beta-Blockers: Drugs like propranolol can decrease blood flow to the liver or alter cardiac output, which may slightly change how the body handles systemic absorption of anesthetics.
• Hyaluronidase: This enzyme is sometimes added to local anesthetics to help them spread through tissues. While often used intentionally, it can increase the speed of tetracaine absorption into the bloodstream, requiring careful dose adjustment.

There are no known significant interactions between tetracaine and specific foods like grapefruit or dairy. However, if you are receiving spinal anesthesia, your doctor will likely instruct you to fast (NPO status) for several hours before the procedure to prevent complications like aspiration.

• St. John's Wort: May theoretically affect the metabolism of many drugs, though its impact on plasma esterase-metabolized drugs like tetracaine is likely minimal.
• Kava and Valerian: These herbs have sedative properties and may increase the CNS-depressing effects of anesthetics.
• Garlic, Ginkgo, and Ginseng: These supplements can have mild blood-thinning effects, which might increase the risk of bruising or bleeding at the site of a tetracaine injection.

Tetracaine does not typically interfere with common blood chemistry or hematology tests. However, the presence of PABA (its metabolite) in the urine can sometimes interfere with certain specialized urine tests. Always inform the lab if you have recently received anesthesia.

Interaction Mechanism Summary

Most interactions with tetracaine occur through one of two mechanisms:

1. 1Pharmacodynamic: Additive effects on sodium channels (e.g., other anesthetics or antiarrhythmics).
2. 2Metabolic: Inhibition of pseudocholinesterase, leading to reduced clearance and increased toxicity.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking before any procedure involving Tetracaine.

Tetracaine must NEVER be used in the following circumstances:

• Known Hypersensitivity: If you have a documented allergy to tetracaine, other ester-type local anesthetics (like procaine, benzocaine, or chloroprocaine), or PABA, the use of tetracaine is strictly prohibited due to the risk of anaphylaxis.
• Inflamed or Infected Tissue: Tetracaine should not be injected into or applied to areas that are actively infected or severely inflamed. The acidic environment of infected tissue prevents the anesthetic from working effectively, and the injection could spread the infection.
• Ophthalmic Self-Administration: Tetracaine is absolutely contraindicated for home use or prolonged use by patients. The risk of permanent corneal melting and blindness is too high.
• Spinal Anesthesia Contraindications: For the spinal route, tetracaine is contraindicated in patients with severe hemorrhage, septicemia (blood infection), or infections at the site of the needle puncture.

In these cases, a doctor will perform a careful risk-benefit analysis:

• Pseudocholinesterase Deficiency: A rare genetic condition where the body lacks the enzyme to break down ester anesthetics. Tetracaine will stay in the system much longer, greatly increasing toxicity risks.
• Heart Block: Because tetracaine can slow electrical conduction in the heart, patients with existing heart block or severe bradycardia must be treated with extreme caution.
• Pre-existing Neurological Disease: In spinal anesthesia, patients with conditions like multiple sclerosis may be at a higher risk, though this is a subject of clinical debate.

Patients should be aware of cross-sensitivity. If you are allergic to sunscreens containing PABA, you are likely allergic to tetracaine. Furthermore, there is no cross-sensitivity between ester anesthetics (like tetracaine) and amide anesthetics (like lidocaine). If you are allergic to tetracaine, your doctor can usually safely use an amide-type anesthetic instead.

> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic conditions, before prescribing or administering Tetracaine.

Tetracaine is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans.

• Trimester-Specific Risks: There is no evidence of specific teratogenicity (birth defects) in humans, but use during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus.
• Labor and Delivery: Tetracaine is frequently used for spinal anesthesia during Cesarean sections. When used correctly for spinal anesthesia, systemic levels in the mother remain low, and it is generally considered safe for the baby.

It is not known whether tetracaine is excreted in human milk. However, because tetracaine is rapidly broken down by enzymes in the mother's blood, the amount that could potentially reach the breast milk is thought to be extremely small. Most clinical guidelines suggest that breastfeeding can be safely resumed once the mother has recovered from the effects of the anesthesia.

Tetracaine is used in children for ophthalmic and topical anesthesia, but with significant precautions.

• Safety: Children are at a higher risk for systemic toxicity because of their smaller body mass.
• Methemoglobinemia: Infants under 6 months of age are at a higher risk for anesthetic-induced methemoglobinemia and should be monitored with pulse oximetry.
• Approved Uses: It is commonly used in 'LAT gel' for numbing lacerations in pediatric emergency rooms.

Patients over age 65 may require adjusted care when receiving tetracaine.

• Spinal Anesthesia: Elderly patients are more prone to significant hypotension (low blood pressure) following spinal anesthesia. Dose reductions of 10-20% are often recommended.
• Cardiovascular Reserve: Older adults may have less 'reserve' to handle the stress of systemic toxicity, making careful dosing and monitoring even more critical.
• Polypharmacy: The higher likelihood of taking beta-blockers or heart medications increases the risk of drug interactions.

In patients with kidney disease, the primary concern is the clearance of tetracaine's metabolites (PABA). While a single dose is usually safe, repeated doses could lead to metabolite buildup, which might cause irritation or allergic sensitization. No specific GFR-based dosing is standardized, but clinical monitoring is advised.

As long as the liver is producing sufficient plasma pseudocholinesterase, tetracaine is safe. However, in end-stage liver disease (Child-Pugh Class C), enzyme production may drop. In these rare cases, the half-life of tetracaine is prolonged, and the risk of systemic toxicity increases significantly.

> Important: Special populations require individualized medical assessment to ensure the safest possible anesthetic outcome.

Tetracaine is a potent inhibitor of voltage-gated sodium channels. At the molecular level, it diffuses across the nerve cell membrane in its uncharged (lipid-soluble) form. Once inside the cell, it becomes ionized and binds to a specific site within the pore of the sodium channel. This binding keeps the channel in an 'inactivated' state, preventing the flow of sodium ions into the cell. This block is 'use-dependent,' meaning the drug works more effectively on nerves that are actively trying to fire. By stopping the electrical current, tetracaine prevents the pain signal from ever reaching the central nervous system.

• Onset of Action: Very rapid. For ophthalmic use, anesthesia occurs within 30 seconds. For spinal use, it occurs within 1 to 5 minutes.
• Duration of Effect: Long-acting. Ophthalmic anesthesia lasts 10–20 minutes. Spinal anesthesia can last 2 to 3 hours, which can be extended to 4-6 hours if a vasoconstrictor like epinephrine is added.
• Potency: Tetracaine is roughly 10 times more potent than procaine.

| Parameter | Value |

|---|---|

| Bioavailability | High (Topical/Mucous Membranes) |

| Protein Binding | 75% - 85% |

| Half-life | ~5 to 10 minutes (Plasma) |

| Tmax | Immediate (Local) |

| Metabolism | Plasma Pseudocholinesterase (Hydrolysis) |

| Excretion | Renal (Metabolites) |

• Molecular Formula: C15H24N2O2
• Molecular Weight: 264.36 g/mol
• Solubility: Very soluble in water; soluble in alcohol.
• Structure: It is an ester of para-aminobenzoic acid (PABA) with a butyl group attached to the nitrogen atom, which contributes to its high lipid solubility and potency.

Tetracaine is an Ester-type Local Anesthetic. It is distinguished from the 'Amide' class (like lidocaine) by its chemical linkage and its metabolism by plasma enzymes rather than the liver. Within the therapeutic area of anesthesiology, it is considered a long-acting local anesthetic.